论文部分内容阅读
在2003年医药行业并购、重组之后,2004年继续上演了并购、重组的故事,并出现了新的并购、重组高潮。在2004年医药行业并购、重组的高潮中,中国医药集团总公司、华源集团等国有大型企业进行的系列并购、重组,特别引人注目,国内医药行业的大鳄正逐步形成。2月,国药集团经过激烈争夺,最终从深圳市投资管理公司手中接过了其持有的43.33%股权,成为一致药业的大股东,结束了包括上药、丽珠、东盛等6家药企对一致药业的拼抢。9月,
After the pharmaceutical industry mergers and acquisitions and restructuring in 2003, the merger and reorganization story continued in 2004, and new climaxes of mergers and acquisitions and restructuring occurred. In 2004, the pharmaceutical industry mergers and acquisitions, the climax of the reorganization, China Pharmaceutical Group Corporation, Huayuan Group and other state-owned large enterprises M & A, restructuring, with particular attention, the domestic pharmaceutical industry is gradually forming predators. In February, after intense competition, Sinopharm Group finally took 43.33% of the equity it held from Shenzhen Investment Management Co., Ltd. and became the major shareholder of Accord Pharmaceutical, ending 6 pharmaceutical companies including Shanghai Pharmaceuticals, Livzon and Tung Shing Pharmaceutical companies scraping for the same medicine. September,